Scinai Immunotherapeutics Ltd - American Depositary Shares — Rendiconto Finanziario (NASDAQ:SCNI) | MetaTrader

Apri il grafico completo

Scinai Immunotherapeutics Ltd - American Depositary Shares

BiondVax Pharmaceuticals Ltd. is an Israeli biopharmaceutical company focused on developing and manufacturing immunotherapeutic products, primarily for the treatment of infectious diseases and autoimmune diseases. In collaboration with the Max Planck Institute for Multidisciplinary Sciences and the University Medical Center Göttingen, both in Germany, BiondVax develops nanosized antibody therapies for diseases such as COVID-19, asthma and psoriasis.

Notizie

Scinai completa riorganizzazione aziendale, separa unità CDMO

Scinai receives expanded grant for robotic manufacturing system

Scinai registra crescita dei ricavi grazie all’espansione del business CDMO

Scinai reports revenue growth as CDMO business expands

Scinai Immunotherapeutics programma l’assemblea annuale per il 22 dicembre

Scinai Immunotherapeutics schedules annual meeting for December 22

Scinai riceve una sovvenzione di $246.000 per espandere la produzione biotecnologica

Scinai receives $246,000 grant to expand biotech manufacturing

Scinai Immunotherapeutics stock soars on promising skin disease drug data

Scinai’s PC111 antibody shows promise for pemphigus treatment

Scinai Reports Q1 2025 Financial Results Highlighting Strong CDMO Revenue Momentum and Reduced Cash Burn